Merck & Co., Inc. Reclassification from AOCI, Current Period, before Tax, Attributable to Parent
Merck & Co., Inc. (MRK) reported Reclassification from AOCI, Current Period, before Tax, Attributable to Parent of $72.00 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-03.
Discontinued › Income Statement › Unrealized Gains
us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent · last filed 2023-11-03
- Merck & Co., Inc. reclassification from aoci, current period, before tax, attributable to parent for the quarter ending 2023-09-30 was $72.00M, a 59.32% decline year-over-year.
- Merck & Co., Inc. reclassification from aoci, current period, before tax, attributable to parent for the quarter ending 2023-06-30 was $34.00M, a 25.93% increase year-over-year.
- Merck & Co., Inc. reclassification from aoci, current period, before tax, attributable to parent for the quarter ending 2023-03-31 was $100.00M, a 334.78% increase year-over-year.
- Merck & Co., Inc. reclassification from aoci, current period, before tax, attributable to parent for the quarter ending 2022-09-30 was $177.00M.
- Merck & Co., Inc. reclassification from aoci, current period, before tax, attributable to parent for fiscal 2015 was $623.00M, a 1419.51% increase from fiscal 2014.
- Merck & Co., Inc. reclassification from aoci, current period, before tax, attributable to parent for fiscal 2014 was $41.00M.
- Merck & Co., Inc. reclassification from aoci, current period, before tax, attributable to parent for fiscal 2013 was -$289.00M.
| Period end | Reclassification from AOCI, Current Period, before Tax, Attributable to Parent 3 month | Reclassification from AOCI, Current Period, before Tax, Attributable to Parent 6 month | Reclassification from AOCI, Current Period, before Tax, Attributable to Parent 9 month | Reclassification from AOCI, Current Period, before Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2023-09-30 | $72.00M 10-Q · filed 2023-11-03 | $106.00M derived: sum of 2 quarters · filed 2023-11-03 | $206.00M 10-Q · filed 2023-11-03 | |
| 2023-06-30 | $34.00M 10-Q · filed 2023-08-07 | $134.00M 10-Q · filed 2023-08-07 | ||
| 2023-03-31 | $100.00M 10-Q · filed 2023-05-05 | |||
| 2022-09-30 | $177.00M 10-Q · filed 2023-11-03 | $204.00M derived: sum of 2 quarters · filed 2023-11-03 | $227.00M 10-Q · filed 2023-11-03 | |
| 2022-06-30 | $27.00M 10-Q · filed 2023-08-07 | $50.00M 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | $23.00M 10-Q · filed 2023-05-05 | |||
| 2021-09-30 | -$104.00M 10-Q · filed 2022-11-03 | -$230.00M derived: sum of 2 quarters · filed 2022-11-03 | -$428.00M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | -$126.00M 10-Q · filed 2022-08-05 | -$324.00M 10-Q · filed 2022-08-05 | ||
| 2021-03-31 | -$198.00M 10-Q · filed 2022-05-05 | |||
| 2020-09-30 | -$94.00M 10-Q · filed 2021-11-05 | -$121.00M derived: sum of 2 quarters · filed 2021-11-05 | -$121.00M 10-Q · filed 2021-11-05 | |
| 2020-06-30 | -$27.00M 10-Q · filed 2021-08-09 | -$28.00M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | -$1.00M 10-Q · filed 2021-05-05 | |||
| 2019-09-30 | $75.00M 10-Q · filed 2020-11-05 | $148.00M derived: sum of 2 quarters · filed 2020-11-05 | $176.00M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $73.00M 10-Q · filed 2020-08-05 | $101.00M 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | $28.00M 10-Q · filed 2020-05-06 | |||
| 2018-09-30 | -$84.00M 10-Q · filed 2019-11-05 | -$216.00M derived: sum of 2 quarters · filed 2019-11-05 | -$365.00M 10-Q · filed 2019-11-05 | |
| 2018-06-30 | -$132.00M 10-Q · filed 2019-08-06 | -$281.00M 10-Q · filed 2019-08-06 | ||
| 2018-03-31 | -$145.00M 10-Q · filed 2019-05-08 | |||
| 2017-09-30 | $7.00M 10-Q · filed 2018-11-06 | $22.00M derived: sum of 2 quarters · filed 2018-11-06 | $146.00M 10-Q · filed 2018-11-06 | |
| 2017-06-30 | $15.00M 10-Q · filed 2018-08-07 | $139.00M 10-Q · filed 2018-08-07 | ||
| 2017-03-31 | $124.00M 10-Q · filed 2018-05-08 | |||
| 2016-09-30 | $39.00M 10-Q · filed 2016-11-07 | $108.00M derived: sum of 2 quarters · filed 2016-11-07 | $255.00M 10-Q · filed 2016-11-07 | $420.00M derived: sum of 4 quarters · filed 2016-11-07 |
| 2016-06-30 | $69.00M 10-Q · filed 2016-08-08 | $216.00M 10-Q · filed 2016-08-08 | $381.00M derived: sum of 3 quarters · filed 2016-08-08 | $522.00M derived: sum of 4 quarters · filed 2016-11-07 |
| 2016-03-31 | $147.00M 10-Q · filed 2016-05-09 | $312.00M derived: sum of 2 quarters · filed 2016-05-09 | $453.00M derived: sum of 3 quarters · filed 2016-11-07 | $597.00M derived: sum of 4 quarters · filed 2016-11-07 |
| 2015-12-31 | $165.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | $306.00M derived: sum of 2 quarters · filed 2016-11-07 | $450.00M derived: sum of 3 quarters · filed 2016-11-07 | $623.00M 10-K · filed 2016-02-26 |
| 2015-09-30 | $141.00M 10-Q · filed 2016-11-07 | $285.00M derived: sum of 2 quarters · filed 2016-11-07 | $458.00M 10-Q · filed 2016-11-07 | $540.00M derived: sum of 4 quarters · filed 2016-11-07 |
| 2015-06-30 | $144.00M 10-Q · filed 2016-08-08 | $317.00M 10-Q · filed 2016-08-08 | $399.00M derived: sum of 3 quarters · filed 2016-08-08 | $404.00M derived: sum of 4 quarters · filed 2016-08-08 |
| 2015-03-31 | $173.00M 10-Q · filed 2016-05-09 | $255.00M derived: sum of 2 quarters · filed 2016-05-09 | $260.00M derived: sum of 3 quarters · filed 2016-05-09 | |
| 2014-12-31 | $82.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | $87.00M derived: sum of 2 quarters · filed 2016-02-26 | $41.00M 10-K · filed 2016-02-26 | |
| 2014-09-30 | $5.00M 10-Q · filed 2015-11-05 | -$41.00M 10-Q · filed 2015-11-05 | ||
| 2013-12-31 | -$289.00M 10-K · filed 2016-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |